BROADCAST SCRIPT

INTRO

AFTER NEARLY SIX DECADES OF RESEARCH – EXPERIMENTS – AND TESTING... THE FOOD AND DRUG ADMINISTRATION HAS OFFICIALLY APPROVED THE FIRST R-S-V VACCINE. WHILE THOSE CURRENTLY ABLE TO GET THE VACCINE ARE ADULTS 60 AND OLDER – PREGNANT MOTHERS MAY SOON BE ABLE TO AS WELL.

TAKE VO

THE VIRUS IS TYPICALLY MILD IN MOST PEOPLE – BUT IT CAN BE EXTREMELY SERIOUS FOR INFANTS AND SOME HIGHER-RISK OLDER ADULTS.
DR. DOUGLAS KASPER IS AN INFECTIOUS DISEASE SPECIALIST WITH OSF HEALTHCARE – HE SAYS THE U.S. IS COMING OFF OF A SEVERE R-S-V SEASON DURING THE WINTER.
HE SAYS IF CURRENT VACCINE TRIALS ARE SUCCESSFUL IN PREGNANT WOMEN – IT COULD PROVIDE LIFE-SAVING ANTIBODIES FOR THEIR BABIES.

20 SECOND SOT

“We’re trying to use the mother’s ability to create an immune response, because the baby cannot do that on their own. So if we can vaccinate during pregnancy, which is the study group we’re awaiting data for, there would be a huge benefit for young children that currently does not exist.”

VO TAG

DR. KASPER SAYS HE HOPES THE RECOMMENDATION FOR VACCINATING PREGNANT WOMEN COMES BY LATE THIS SUMMER.
THE AREXVY VACCINE IS A SINGLE-DOSE SHOT. DR. KASPER SAYS THIS VACCINE IS MUCH DIFFERENT FROM THE ONE FOR COVID-19 – AND MUCH MORE SIMILAR TO A FLU VACCINE.

VO/SOT # 2

AFTER NEARLY SIX DECADES OF RESEARCH – EXPERIMENTS – AND TESTING... THE FOOD AND DRUG ADMINISTRATION HAS OFFICIALLY APPROVED THE FIRST R-S-V VACCINE. WHILE THOSE CURRENTLY ABLE TO GET THE VACCINE ARE ADULTS 60 AND OLDER – PREGNANT MOTHERS MAY SOON BE ABLE TO AS WELL.

TAKE VO
THE VIRUS IS TYPICALLY MILD IN MOST PEOPLE – BUT IT CAN BE EXTREMELY SERIOUS FOR INFANTS AND SOME HIGHER-RISK OLDER ADULTS.

DR. DOUGLAS KASPER IS AN INFECTIOUS DISEASE SPECIALIST WITH OSF HEALTHCARE – HE SAYS WHILE THOSE ELIGIBLE FOR THE VACCINE ARE LIMITED RIGHT NOW... HE HOPES THE RECOMMENDATION EXPANDS TO INCLUDE MORE PEOPLE BY THE END OF SUMMER. INCLUDING PREGNANT WOMEN.

20 SECOND SOT

“There are ongoing trials looking at vaccinating mothers who are pregnant. This would be for potential protection of unborn children, but that has not been approved yet. There’s expected re-evaluation of that data coming this summer. Hopefully by August we get some updated patient groups.”

VO TAG

THE AREXVY VACCINE IS A SINGLE-DOSE SHOT. DR. KASPER SAYS THIS VACCINE IS MUCH DIFFERENT THAN THE ONE FOR COVID-19 – AND MUCH MORE SIMILAR TO A FLU VACCINE. IT EXPOSES THE PERSON TO A PROTEIN FROM THE VIRUS – WHICH THEN MAKES THEM HAVE AN IMMUNE RESPONSE... AND PROTECTS THEM IN THE FUTURE IF THEY’RE EVER EXPOSED TO THE VIRUS.